Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct;11(5):755-758.
doi: 10.21037/hbsn-22-386.

Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective

Luis Antonio Díaz  1 , Marco Arrese  1 , Juan Pablo Arab  1   2   3
Affiliations
Editorial

Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective

Luis Antonio Díaz et al. Hepatobiliary Surg Nutr. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-386/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Trends in (A) prevalence of NAFLD and (B) incidence of NAFLD-related HCC according to WHO regions. Data were obtained from the Global Burden of Disease Collaborative Network. Seattle, United States of America: Institute for Health Metrics and Evaluation, 2022. NAFLD, non-alcoholic fatty liver disease; HCC, hepatocellular carcinoma; WHO, World Health Organization.
See this image and copyright information in PMC

Comment on

References

    1. Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022;56:942-56. 10.1111/apt.17158 - DOI - PubMed
    1. Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-33. 10.1002/hep.29466 - DOI - PMC - PubMed
    1. Arab JP, Barrera F, Gallego C, et al. High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. Ann Hepatol 2016;15:721-8. - PubMed
    1. Arab JP, Dirchwolf M, Álvares-da-Silva MR, et al. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol 2020;19:674-90. 10.1016/j.aohep.2020.09.006 - DOI - PubMed
    1. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71:778-88. 10.1136/gutjnl-2021-324191 - DOI - PubMed